CD47 and neoplasm: Finally, we will discuss the anti-PD-L1 and anti-CD47 antibodies, which are not tumor-expressed ligands of immune checkpoints, and which mandate a different reasoning from that underlying the targeting of checkpoints expressed on immune cells.